All In Biotech

Investigational drug · Phase 2

HSK39297 200mgQD

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for IgA Nephropathy (IgAN), Lupus Nephritis (LN).

Phase 2

Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

3

2 still active

All registered trials

4

Any phase or sponsor naming "HSK39297 200mgQD"

First trial start

2024

Oct 12, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HSK39297 200mgQD", any sponsor or status.

Conditions studied

As listed on its trial records.

  • IgA Nephropathy (IgAN)
  • Lupus Nephritis (LN)

Approved drugs for the same conditions: Lupus (SLE) · IgA nephropathy · Immunology and inflammation · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "HSK39297 200mgQD" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for IgA Nephropathy (IgAN)

  • FUB523zigakibart, BION-1301Phase 36 trials

    Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)

  • HSK39297Phase 35 trials

    Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH)

  • MY008211APhase 35 trials

    Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)

  • JADE101Phase 32 trials

    Jade Biosciences, Inc. · IgA Nephropathy (IgAN), IgA Nephropathy

  • SC0062Phase 31 trial

    Biocity Biopharmaceutics Co., Ltd. · IgA Nephropathy (IgAN)

  • HSK39297 300mgQDPhase 22 trials

    Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)

  • SGB-9768Phase 22 trials

    Suzhou Sanegene Bio Inc. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN), C3 Glomerulopathy

  • SLN12140Phase 22 trials

    Linno Pharmaceuticals, Inc. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria (PNH)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.